{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:25:36Z","timestamp":1742012736804,"version":"3.38.0"},"reference-count":52,"publisher":"JLE","issue":"7","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.nephro.2011.11.003","type":"journal-article","created":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T08:36:55Z","timestamp":1322728615000},"page":"592-598","source":"Crossref","is-referenced-by-count":0,"title":["Traitement immunosuppresseur"],"prefix":"10.1684","volume":"7","author":[{"given":"Patrick","family":"Niaudet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2011.11.003_bib0005","first-page":"146","article-title":"Renal transplantation in children from 1987\u20131996: the 1996\u00a0annual report of the north american pediatric renal transplant cooperative study","volume":"1","author":"Feld","year":"1997","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1399-3046.2005.00296.x","article-title":"A randomized multicenter trial of OKT3\u00a0mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation","volume":"9","author":"Benfield","year":"2005","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0015","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1600-6143.2006.01367.x","article-title":"A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation","volume":"6","author":"Grenda","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0020","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/TP.0b013e318188af15","article-title":"Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids","volume":"86","author":"Offner","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/TP.0b013e3181ac6833","article-title":"Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results","volume":"88","author":"Chavers","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0030","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/TP.0b013e3181fc8937","article-title":"Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation","volume":"90","author":"Li","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00853215","article-title":"Anti-OKT3\u00a0response following prophylactic treatment in paediatric kidney transplant recipients","volume":"7","author":"Niaudet","year":"1993","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2011.11.003_bib0040","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1600-6143.2005.00879.x","article-title":"Campath-1H use in pediatric renal transplantation","volume":"5","author":"Bartosh","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0045","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/TP.0b013e31816a8a6d","article-title":"Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody","volume":"85","author":"Shapiro","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(89)90237-7","article-title":"Gene regulation by steroid hormones","volume":"56","author":"Beato","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.nephro.2011.11.003_bib0055","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI116353","article-title":"Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glu-cocorticoids through interference with nuclear transcription factors AP-1\u00a0and NF-AT","volume":"91","author":"Paliogianni","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2011.11.003_bib0060","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0022-3476(05)80234-3","article-title":"Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation","volume":"120","author":"Broyer","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.nephro.2011.11.003_bib0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00007890-199601150-00008","article-title":"Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American pediatric renal transplant cooperative study","volume":"61","author":"Jabs","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-6143.2009.02767.x","article-title":"A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation","volume":"10","author":"Benfield","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0075","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1600-6143.2010.03047.x","article-title":"A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study","volume":"10","author":"Grenda","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0080","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/TP.0b013e31819b6d4a","article-title":"Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil","volume":"87","author":"Hocker","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00007890-199001000-00017","article-title":"Follow-up of cyclos-porine-treated pediatric renal allograft recipients after cessation of prednisone","volume":"49","author":"Reisman","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0090","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection","volume":"345","author":"European mycophenolate mofetil cooperative study group","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2011.11.003_bib0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","article-title":"A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation","volume":"61","author":"The tricontinental mycophenolate mofetil renal transplantation study group","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US renal transplant mycophenolate mofetil study group","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007890-200007270-00010","article-title":"Conversion from azathioprine (correction of azathioprina) to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection","volume":"70","author":"Ferraris","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1399-0012.1996.tb00660.x","article-title":"Rescue therapy with mycophenolate mofetil","volume":"10","author":"The mycophenolate mofetil renal refractory rejection study group","year":"1996","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0115","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0120","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":"Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0125","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s004670100006","article-title":"The use of mycophenolate mofetil suspension in pediatric renal allograft recipients","volume":"16","author":"Bunchman","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2011.11.003_bib0130","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine","volume":"321","author":"Kahan","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2011.11.003_bib0135","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1084\/jem.163.5.1037","article-title":"Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth","volume":"163","author":"Kehrl","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.nephro.2011.11.003_bib0140","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.nephro.2011.11.003_bib0145","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00007890-199409000-00004","article-title":"Cyclosporine pharmacokinetics and variability from a microemulsion formulation \u2013 a multicenter investigation in kidney transplant patients","volume":"58","author":"Kovarik","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0150","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/00007890-199404270-00007","article-title":"Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients \u2013 a concentration-controlled comparison with the commercial formulation","volume":"57","author":"Mueller","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0155","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/BF00856658","article-title":"Practical aspects in the use of cyclosporin in paediatric nephrology","volume":"5","author":"Hoyer","year":"1991","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2011.11.003_bib0160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1681\/ASN.V12162","article-title":"Cellular and molecular mechanisms of cyclosporin nephrotoxicity","volume":"1","author":"Kopp","year":"1990","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2011.11.003_bib0165","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1681\/ASN.V22s45","article-title":"Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury","volume":"2","author":"Myers","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2011.11.003_bib0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1399-0012.1994.tb00097.x","article-title":"FK 506: an update","volume":"8","author":"Klintmalm","year":"1994","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1399-3046.2003.00079.x","article-title":"Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a Naprtcs study","volume":"7","author":"Neu","year":"2003","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0180","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00467-001-0795-9","article-title":"Randomized trial of tacrolimus vs. cyclosporin microemulsion in renal transplantation","volume":"17","author":"Trompeter","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2011.11.003_bib0185","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1399-3046.2005.00334.x","article-title":"Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion","volume":"9","author":"Filler","year":"2005","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0025-6196(12)61034-9","article-title":"Nephrotoxic effects of primary immunosuppression with FK-506\u00a0and cyclosporine regimens after liver transplantation","volume":"69","author":"Porayko","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.nephro.2011.11.003_bib0195","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2006010049","article-title":"Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation","volume":"17","author":"Harmon","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2011.11.003_bib0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ki.1996.28","article-title":"The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients","volume":"49","author":"Murgia","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2011.11.003_bib0205","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0210","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/01.TP.0000140868.88149.63","article-title":"Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue","volume":"78","author":"Butani","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0215","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJM200511103531922","article-title":"Post-transplantation proteinuria and sirolimus","volume":"353","author":"Izzedine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2011.11.003_bib0220","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.TP.0000151630.25127.3A","article-title":"Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy","volume":"79","author":"Mahe","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0225","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1600-6143.2008.02267.x","article-title":"Sirolimus may reduce fertility in male renal transplant recipients","volume":"8","author":"Zuber","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0230","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1399-3046.2007.00832.x","article-title":"Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year","volume":"12","author":"Ettenger","year":"2008","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0235","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.TP.0000060252.57111.AC","article-title":"Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection","volume":"75","author":"Rocha","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0240","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.TP.0000122187.76518.BC","article-title":"Treatment of C4d-positive acute humoral rejection with plasmaphe-resis and rabbit polyclonal antithymocyte globulin","volume":"77","author":"Shah","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0245","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/01.TP.0000128194.55934.48","article-title":"Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection","volume":"78","author":"White","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0250","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1600-6143.2004.00454.x","article-title":"Rituximab as treatment for refractory kidney transplant rejection","volume":"4","author":"Becker","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2011.11.003_bib0255","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2011.11.003_bib0260","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination Plasmapheresis\/IVIg\/anti-CD20\u00a0versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725511006171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725511006171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2011.11.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T17:20:28Z","timestamp":1741972828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725511006171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1769725511006171"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2011.11.003","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}